Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV-44749 in Chinese Patients With Schizophrenia
NCT06253546Phase 1Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TEV-749 in schizophrenia (3 cohorts), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Treatment Emergent Serious Adverse Events and 1 more. Started Mar 2024; status: completed.
02
Drugs
TEV-749
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06253546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253546.